Board appointment at AP Pharma
This article was originally published in Scrip
AP Pharma, a speciality pharmaceutical company developing products using its proprietary Biochronomer polymer-based drug delivery technology, has appointed Stephen Davis to its board of directors. He was the chief executive officer for Neurogen, which was recently acquired by Ligand Pharmaceuticals. His appointment brings the number of AP Pharma board members to seven. The company's main focus is on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting.